Top News

Full FDA Approval Sought By Pfizer-BioNTech For Covid-19 Vaccine

Full approval for the Covid-19 vaccine was sought by Pfizer coupled with its German counterpart BioNTech this Friday. This was through an application directed to the Food and Drug Administration authority.

Full FDA Approval Sought By Pfizer-BioNTech For Covid-19 Vaccine

A process that was followed with an announcement that stated how data is going to be fed to the FDA on a rollover basis for the next couple of weeks. Thus, seeking a prioritized review of the same since there is no clarity on how long the review process is going to take. 

A tag of emergency use authorization is how the vaccines are being provided by Pfizer-BioNTech, unlike the other vaccines made available across the U.S. 

The emergency usage tag enabled Pfizer to provide data that ensures safety and effectiveness amongst the trial participants through tracking. One whose tracking tenure has been cut from the initial decider of six months to two months.

The FDA quoted how amidst the pandemic raging the country, the priority was laid on to provide the vaccines as fast as possible. Generally, the side effects appear between four to six weeks after people are administered the vaccine shot. 

There have been several instances wherein people have showcased hesitancy. This is primarily due to the unavailability of data for the long term. 

Since the availability of the Pfizer-BioNTech vaccine was made in December, there is enough data and information to showcase. The 134 million shots to Americans as well as the trials are proof enough to determine the vaccine’s safety and efficacy in preventing Covid-19.

The Pfizer-BioNTech vaccine has showcased no further issues in regards to its safety since it was authorized for usage. The data was compiled by the Centers for Disease Control and Prevention following the companies and periodic safety reviews. 

Pfizer’s CEO, Albert Bourla, stated how the company had achieved great progress by making the vaccine available to millions of Americans since December. This was possible only because of the collaboration with the government of the U.S. 

The future holds a complete rollout of the submission, thereby supporting the review, which would enable Pfizer a full regulatory approval for the Covid-19 vaccine. One that is targeted for the coming few months.

The approval is set to include people over and above 16 years of age. There is a possibility for the vaccines to be allowed for children between 12 to 15 years of age, which the FDA could sanction any given day. However, Pfizer is only going to seek approval once there is enough data for a minimum of six months. 

The large-scale trials of the Pfizer-BioNTech vaccine that lasted the previous summer are going to continue for two years to come. This is especially amongst the participants for ensuring safety and effectiveness throughout. 

There is speculation related to the effectiveness of the Covid-19 vaccine, but reports and evidence confirm the same to be protective for a year. 

The president cum CEO of Biologics Consulting pointed out the major difference between full approval and emergency usage authorization. One that is psychological and which will not have any operational effects. The effect could be perceptive wise or even related to hesitance. 

The executive director for the International Vaccine Access Center, William Moss, corroborated how the prime benefit for a full approval will be increased confidence. 

Baylor mentioned how the benefits for vaccination stated by the FDA said it boasts of enough potential in outweighing the risks. But the sanction of full approval is an acknowledgment. An acceptance that the benefits far outweigh the risks.  

The procedure of full approval could also let the employers empower their workers in getting the designated shots. There has been hesitance; Moss quipped, which mainly stemmed since the vaccine had approval from EUA and not a formal one.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

To Top